Correction: Correspondence to "A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development" [0.03%]
关于“新型长链非编码RNA SNHG29通过调节EP300相关组蛋白乙酰化修饰抑制FLT3-ITD AML发生”的致歉及更正通知
Xiaoyang Wang,Hang Yao,Jiahao Chen et al.
Xiaoyang Wang et al.
Published Erratum
Leukemia. 2025 Nov 21. DOI:10.1038/s41375-025-02813-1 2025
Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma [0.03%]
纠正：发散的分子途径驱动单态上皮细胞嗜好性和与肠病相关的肠T细胞淋巴瘤的不同分子路径
David Vallois,Edoardo Missiaglia,Luis Veloza et al.
David Vallois et al.
Published Erratum
Leukemia. 2025 Nov 20. DOI:10.1038/s41375-025-02808-y 2025
Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases [0.03%]
通过外显子组测序鉴定的多发性骨髓瘤易感基因
Maroulio Pertesi,Delphine Demangel,Abhishek Niroula et al.
Maroulio Pertesi et al.
Multiple myeloma (MM) is the second most common blood malignancy, with several lines of evidence supporting an inherited genetic component. Here, we sequenced 177 affected individuals from 128 families, and 170 early-onset MM cases diagnose...
Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes [0.03%]
采用自适应采样长读纳米孔DNA测序鉴定酪氨酸激酶融合基因
Matthew Salmon,Nicole Naumann,Jenny Rinke et al.
Matthew Salmon et al.
Diverse haematological neoplasms are driven by tyrosine kinase (TK) fusion genes formed by recurrent or non-recurrent genomic rearrangements. The resulting chimeric proteins often present excellent targets for treatment with kinase inhibito...
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint [0.03%]
阿维克替尼与伊马替尼联合早期 switching 从伊马替尼转换为阿维克替尼以获得新诊断慢性粒细胞白血病患者的自由缓解：第一个主要终点分析
Fausto Castagnetti,Massimo Breccia,Elisabetta Abruzzese et al.
Fausto Castagnetti et al.
Treatment-free remission is one of the most important goals of CML treatment but so far, the best treatment to reach this aim is still undefined, even though it is widely accepted that a sustained DMR is the prerequisite to discontinue TKI....
Oncogenic activation of EVC/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia [0.03%]
EVC/EVC2致癌活化定义了一组可治疗靶向的急性髓系白血病亚型
Pinpin Sui,Ying Li,Juyeong Hong et al.
Pinpin Sui et al.
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by high incidence, poor prognosis, and marked genetic and clinical heterogeneity. This heterogeneity poses a significant challenge to effective treatment and...
Florian H Heidel,Martin Griesshammer,Jean-Jacques Kiladjian;PV-AIM investigators
Florian H Heidel
Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study [0.03%]
儿童高危首次复发B细胞急性淋巴细胞白血病患者中.BLINATUMOMAB巩固治疗的最终五年随访分析：一项随机多中心III期研究
Franco Locatelli,Carmelo Rizzari,Bernd Gruhn et al.
Franco Locatelli et al.
The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma [0.03%]
IL-1R和NFKBIZ通路介导了间变性大细胞淋巴瘤中的免疫调控反应及免疫治疗敏感性
Wei Wei,Zhihui Song,Yajun Wang et al.
Wei Wei et al.
Anaplastic large cell lymphoma (ALCL), an aggressive T-cell malignancy, is marked by elevated expression of CD30 and the immune checkpoint molecule PD-L1. While CD30-directed chimeric antigen receptor (CAR) therapies have demonstrated clini...
Correspondence to "Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis" [0.03%]
关于"MUSASHI2-DEPTOR-KIF11轴对代谢适应和白血病进展的调节"的来信
Hanxue Zheng,Liansheng Zhang,Lijuan Li
Hanxue Zheng